Cardiol Therapeutics Class Stock Performance

Cardiol Therapeutics Relative Risk vs. Return Landscape

If you would invest  113.00  in Cardiol Therapeutics Class on October 31, 2025 and sell it today you would lose (15.00) from holding Cardiol Therapeutics Class or give up 13.27% of portfolio value over 90 days. Cardiol Therapeutics Class is currently does not generate positive expected returns and assumes 3.4548% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Cardiol, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.Given the investment horizon of 90 days Cardiol Therapeutics is expected to under-perform the market. In addition to that, the company is 4.58 times more volatile than its market benchmark. It trades about -0.05 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

Cardiol Therapeutics Target Price Odds to finish over Current Price

Given the investment horizon of 90 days the stock has the beta coefficient of 1.38 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cardiol Therapeutics will likely underperform. Additionally Cardiol Therapeutics Class has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.

Predictive Modules for Cardiol Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cardiol Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Hype Prediction Low Estimated High 0.05 1.00 4.45 Details

Intrinsic Valuation Low Real High 0.13 2.67 6.12 Details

Naive Forecast Low Next High 0.02 1.00 4.45 Details

5 Analysts Consensus Low Target High 7.17 7.88 8.74 Details

Cardiol Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Cardiol Therapeutics is not an exception. The market had few large corrections towards the Cardiol Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cardiol Therapeutics Class, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cardiol Therapeutics within the framework of very fundamental risk indicators.

Cardiol Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cardiol Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cardiol Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.

Cardiol Therapeutics Price Density Drivers

Cardiol Therapeutics Fundamentals Growth

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. Projected growth potential of Cardiol fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cardiol Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.

Understanding Cardiol Therapeutics requires distinguishing between market price and book value, where the latter reflects Cardiol's accounting equity. The concept of intrinsic value—what Cardiol Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cardiol Therapeutics' price substantially above or below its fundamental value.

It's important to distinguish between Cardiol Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiol Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiol Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.